medcelerator · clinician one-pager
New Weekly Infusion for Children with Hunter Syndrome
Avlayah (tividenofusp alfa-eknm) for neurologic Hunter syndrome (MPS II)
FDA Approved · United States · September 7, 2026
Condition: Hunter Syndrome
Who this is for
Avlayah is a weekly infusion for the brain effects of Hunter syndrome in children of at least 5 kilograms. The United States gave it accelerated approval in March 2026. More proof of benefit is required.
Next clinical step
The US Food and Drug Administration (FDA) has approved this medicine. In the United States, ask your doctor or a specialist whether it suits you. They can write a prescription. Insurance or public drug plan coverage is not guaranteed.
Ways to access this treatment
United States · Prescription
US prescription (FDA-labelled)
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761485s000lbl.pdf
General resources for further research
ClinicalTrials.gov
US National Library of Medicine registry of clinical studies. Search by condition, drug, NCT number, and location. A listing is not enrolment, eligibility, or funding. Talk with the trial contact and a clinician before assuming a slot exists.
https://clinicaltrials.gov/
AI-produced discussion aid; not prescribing instructions. Approval does not establish coverage. Full article: https://medcelerator.com/articles/avlayah-tividenofusp